Double vs. single immunotherapy: new hope for Tough-to-Treat bile duct cancer?
NCT ID NCT07369791
Summary
This study is testing if adding a second immunotherapy drug (relatlimab) to a standard treatment improves outcomes for adults with advanced bile duct cancer who haven't had prior treatment. About 76 participants will be randomly assigned to receive either the two-drug immunotherapy combo plus chemotherapy or the single immunotherapy drug plus chemotherapy. The main goal is to see which group has more patients whose tumors shrink significantly.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER(BTC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
Taichung, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital,
Kaohsiung City, Taiwan
-
MacKay Memorial Hospital
Taipei, Taiwan
-
National Cheng Kung University Hospital
Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
Tri-Service General Hospital
Taipei, Taiwan
Conditions
Explore the condition pages connected to this study.